Verzenio (abemaciclib)

This case represents a rare report of surgical resection for breast cancer liver metastasis after CDK4/6 inhibitor-based therapy. It suggests that local treatment may be effective even in cases with suspected endocrine-resistant disease and provides practical insight into patient selection and treatment strategies, as the case fulfilled previously reported criteria for local therapy.

This study demonstrates that adjuvant abemaciclib+ET is being used at the labeled dosage in most Japanese patients. Furthermore, 2-year completion rates in patients with 2-year follow-up were comparable to the clinical trial data from monarchE (69%).

The majority of patients (72%) were treated in the first-line setting; 11 received ribociclib, 15 received palbociclib, and 3 received abemaciclib. Whether this translates into deferring disease progression requires randomized studies with larger treatment groups. To our knowledge, this study represents the first analysis evaluating 18F-FDG-PET/CT-guided SBRT in combination with CDK4/6 inhibitor-based therapy in patients with metastatic breast cancer.

P2, N=33, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027

Palbociclib, ribociclib, and abemaciclib, which are FDA-approved CDK4/6 inhibitors, constitute the standard first-line treatment for advanced hormone receptor-positive (HR+) breast cancers. Collectively, this study deepens the understanding of shared and drug-specific molecular characteristics and mechanisms of CDK4/6 inhibitors at multi-omic levels. Moreover, it provides an experimental basis and potential directions for customizing combination therapies based on pathway vulnerabilities, as well as exploration of novel therapeutic modes and drugs.

TTL measured using OSNA predicts ≥ 4 metastatic LNs in patients with luminal-like BC, with a proposed optimal threshold of 100,000 copies/µL.

P1, N=46, Completed, Ono Pharmaceutical Co., Ltd. | Active, not recruiting --> Completed

Dedifferentiated liposarcoma is a rare mesenchymal malignancy driven by amplification of chromosome 12q13-15, which includes the oncogenes CDK4 and MDM2. These fractionally resistant cells were defined by selective enrichment of cyclin-dependent kinase 2 (CDK2), cyclin B1, and phosphorylated ribosomal protein S6 (pS6), and showed enhanced sensitivity to the CDK2 inhibitor, tagtociclib. Together, these findings reveal nongenetic cell cycle plasticity as a mechanism of escape from CDK4/6 inhibition in dedifferentiated liposarcoma and nominate CDK2 and the PI3K-mTOR pathway as candidate targets for combination therapy.

MBR-01 may effectively mitigate abemaciclib-induced diarrhea, likely through the achievement of stabilization of gut microbiota composition. Larger prospective studies are warranted to validate these preliminary findings.

This article mainly reviews the mechanisms of action, clinical efficacy, and current application status of CDK4/6 inhibitors, including Palbociclib, Ribociclib, Abemaciclib, and the emerging Dalpiciclib. Strategies such as combining phosphoinositide 3-kinase (PI3K) inhibitors, immunotherapy, or new estrogen receptor (ER)-degrading agents are being actively explored for drug-resistant patients. The personalized precision therapy may become the core direction for optimizing the application of CDK4/6 inhibitors in the future, which will improve patients' quality of life.

It also increased reactive oxygen species (ROS) production, caused DNA damage, inhibited DNA damage repair, activated the p53/p21 pathway, and ultimately induced apoptosis. These findings provide preclinical evidence that establishes abemaciclib as a promising novel treatment strategy for retinoblastoma.

A 59-year-old woman with stage IIIA HR+/HER2- breast cancer underwent modified radical mastectomy in 2016, followed by adjuvant AC-P (doxorubicin hydrochloride 70 mg, cyclophosphamide 800 mg, and paclitaxel liposomes 180 mg) chemotherapy, radiotherapy, and letrozole maintenance...Since palbociclib was not yet covered by insurance, she received an initial chidamide + exemestane therapy, which proved ineffective. Using second-line palbociclib combined with fulvestrant and zoledronic acid therapy, disease stabilization was achieved for up to 12 months...As of September 2023, the patient has remained progression-free for >20 months and experienced only manageable grade 2 diarrhea. This case suggests that sequential CDK4/6 inhibition could help achieve >20 months of progression-free disease control in a patient with bone-only HR+/HER2- MBC after clinical progression during prior palbociclib-based therapy and underscored the need for biomarker-guided strategies in this distinct population.